Naslov
The relevance of macrocytosis induction during neoadjuvant dose-dense chemotherapy in breast cancer patients.

Autori
Boraska Jelavić, Tihana ; Podrug, Mario ; Ban, Marija ; Belac Lovasić, Ingrid ; Curić, Zvonimir ; Vrdoljak, Eduard

Izvornik
Anti-cancer drugs (0959-4973) 33 (2022), 1; E655-e661

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
breast cancer ; neoadjuvant dose-dense chemotherapy ; macrocytosis

Sažetak
The aim of this study was to explore the red blood cell changes that occur during neoadjuvant dose- dense chemotherapy (NAC) of breast cancer. Also, we investigated the role of macrocytosis as a predictive biomarker for pathological complete response and disease-free survival (DFS) in these patients. A retrospective analysis of 82 breast cancer patients' data treated with anthracycline- cyclophosphamide-paclitaxel (AC-T) NAC in three oncology institutions in south Croatia from 2013 to 2020 was carried out. During chemotherapy mean corpuscular volume increased with time, with a median increase of 7.25 fl. Macrocytosis was induced in 38% of patients overall. Development of macrocytosis did not correlate with DFS [hazard ratio = 0.525 ; 95% confidence interval (CI), 0.074-3.768 ; P = 0.525]. Higher percentage of patients in macrocytosis group achieved PCR, 39% vs. 29% in no macrocytosis group, but this difference was not statistically significant. The relevance of macrocytosis induction during dose- dense neoadjuvant chemotherapy in breast cancer should be further explored.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA